Go Pro

BGM Group (BGM) Competitors

BGM Group logo
$0.30 0.00 (-0.13%)
As of 02:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BGM vs. PLYX, CPIX, RFL, ICCC, and HRTX

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Polaryx Therapeutics (PLYX), Cumberland Pharmaceuticals (CPIX), Rafael (RFL), ImmuCell (ICCC), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceuticals" industry.

How does BGM Group compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Polaryx Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 312.82%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
Polaryx TherapeuticsN/A N/A N/A
BGM Group N/A N/A N/A

In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company Overall Sentiment
Polaryx Therapeutics Neutral
BGM Group Neutral

Polaryx Therapeutics has higher earnings, but lower revenue than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Polaryx TherapeuticsN/AN/A-$8.98M-$0.05N/A
BGM Group$37.92M0.77-$19.94MN/AN/A

Summary

Polaryx Therapeutics beats BGM Group on 4 of the 5 factors compared between the two stocks.

How does BGM Group compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Cumberland Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cumberland Pharmaceuticals$22.30M5.34-$2.84M-$0.71N/A
BGM Group$37.92M0.77-$19.94MN/AN/A

In the previous week, Cumberland Pharmaceuticals had 5 more articles in the media than BGM Group. MarketBeat recorded 5 mentions for Cumberland Pharmaceuticals and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.78 indicating that BGM Group is being referred to more favorably in the news media.

Company Overall Sentiment
Cumberland Pharmaceuticals Negative
BGM Group Neutral

BGM Group has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. BGM Group's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals-34.40% -26.77% -8.97%
BGM Group N/A N/A N/A

Summary

BGM Group beats Cumberland Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does BGM Group compare to Rafael?

BGM Group (NASDAQ:BGM) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

BGM Group has higher revenue and earnings than Rafael.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M0.77-$19.94MN/AN/A
Rafael$920K109.37-$30.52M-$0.68N/A

In the previous week, BGM Group's average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company Overall Sentiment
BGM Group Neutral
Rafael Neutral

BGM Group has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. BGM Group's return on equity of 0.00% beat Rafael's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Rafael -3,321.74%-41.27%-35.32%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Rafael
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

11.3% of Rafael shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BGM Group has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Summary

BGM Group beats Rafael on 7 of the 9 factors compared between the two stocks.

How does BGM Group compare to ImmuCell?

BGM Group (NASDAQ:BGM) and ImmuCell (NASDAQ:ICCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ImmuCell
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

ImmuCell has lower revenue, but higher earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M0.77-$19.94MN/AN/A
ImmuCell$27.64M3.57-$1.04M-$0.06N/A

13.5% of ImmuCell shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ImmuCell had 4 more articles in the media than BGM Group. MarketBeat recorded 4 mentions for ImmuCell and 0 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company Overall Sentiment
BGM Group Neutral
ImmuCell Neutral

BGM Group has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. BGM Group's return on equity of 0.00% beat ImmuCell's return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
ImmuCell -1.82%-1.88%-1.22%

Summary

BGM Group beats ImmuCell on 6 of the 10 factors compared between the two stocks.

How does BGM Group compare to Heron Therapeutics?

BGM Group (NASDAQ:BGM) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

BGM Group has higher earnings, but lower revenue than Heron Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M0.77-$19.94MN/AN/A
Heron Therapeutics$150.71M0.46-$20.19M-$0.18N/A

Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 446.45%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Heron Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Heron Therapeutics had 9 more articles in the media than BGM Group. MarketBeat recorded 9 mentions for Heron Therapeutics and 0 mentions for BGM Group. Heron Therapeutics' average media sentiment score of 0.78 beat BGM Group's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
BGM Group Neutral
Heron Therapeutics Positive

BGM Group has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

80.0% of Heron Therapeutics shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BGM Group has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. BGM Group's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Heron Therapeutics -20.53%-7,747.30%-8.94%

Summary

BGM Group and Heron Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGM vs. The Competition

MetricBGM GroupPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$29.26M$11.91B$7.04B$12.92B
Dividend YieldN/A2.69%2.58%10.20%
P/E RatioN/A788.55269.9524.78
Price / Sales0.77968.18650.49107.95
Price / CashN/A15.1228.8937.44
Price / Book0.0710.3211.256.43
Net Income-$19.94M$2.77B$3.45B$347.27M
7 Day Performance3.09%1.96%3.49%2.53%
1 Month Performance-10.45%-1.59%-0.66%-1.03%
1 Year Performance-96.10%191.11%77.20%23.28%

BGM Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGM
BGM Group
0.4578 of 5 stars
$0.30
-0.1%
N/A-96.1%$29.26M$37.92MN/A298
PLYX
Polaryx Therapeutics
3.2988 of 5 stars
$2.23
+1.8%
$8.50
+281.2%
N/A$111.16MN/AN/A11
CPIX
Cumberland Pharmaceuticals
0.3771 of 5 stars
$7.80
+8.6%
N/A+141.5%$107.58M$44.52MN/A80
RFL
Rafael
0.2625 of 5 stars
$1.90
-4.8%
N/A+26.7%$104M$920KN/A20
ICCC
ImmuCell
0.8936 of 5 stars
$11.07
+0.3%
N/A+65.2%$99.88M$27.64MN/A70

Related Companies and Tools


This page (NASDAQ:BGM) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners